(October 17, 2016, 12:55 PM EDT) -- SANTA ANA, Calif. — Defendants in a securities class action lawsuit against a pharmaceutical company and certain of its executive officers have failed to show that the lead plaintiff in the action failed to plead falsity, scienter or adequacy of the allegations in arguing that the defendants misrepresented the clinical trial results for a breast cancer treatment drug the company was developing, a federal judge in California ruled Sept. 30 in denying the defendants’ motion to dismiss (Hsingching Hsu v. Puma Biotechnology Inc., et al., No. 15-0865, C.D. Calif.; 2016 U.S. Dist. LEXIS 136527)....